Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

Nvidia Shares Face Market Skepticism Despite Strategic AI Partnership

Dieter Jaworski by Dieter Jaworski
December 1, 2025
in AI & Quantum Computing, Market Commentary, Nasdaq, Semiconductors, Tech & Software
0
Nvidia Stock
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

Nvidia finds itself in a paradoxical position. On the very day the semiconductor leader announced a significant collaborative agreement with Microsoft and AI startup Anthropic, its stock price moved into negative territory. Instead of sparking a rally, the news was met with investor caution, sending shares down to approximately $177 and testing crucial technical support levels. This raises a compelling question: why is the market overlooking positive developments?

Technical Weakness Overshadows Strong Fundamentals

From a fundamental perspective, Nvidia’s position appears robust. In late November, the company reported record-breaking financial results, with third-quarter revenue soaring to $57 billion—a year-over-year increase of 62%. Its order books are full, margins remain healthy, and the new partnership with Anthropic secures potential long-term revenue streams beyond its core AI training business. This collaboration emphasizes the growing “inference” market, which involves the ongoing operation of AI models and requires sustained computing power.

However, the technical chart picture is concerning. The $175 level is widely viewed by traders as a critical support zone, situated near the stock’s 200-day moving average. A sustained break below this point could potentially trigger an acceleration of selling pressure. Market analysts note that while the average consensus price target for Nvidia shares remains above $250, the near-term momentum has decidedly weakened.

“Sell the News” Reaction Dampens Partnership Announcement

The details of the announced partnership are strategically important. Nvidia, Microsoft, and Anthropic are joining forces to massively scale the Claude family of AI models. The initiative will utilize Nvidia’s high-performance chips through Microsoft’s Azure cloud platform to build infrastructure for next-generation “agent AI”—autonomous systems capable of handling complex tasks. This deal represents a strategic milestone for Nvidia, reinforcing its dominance in the AI hardware sector.

Should investors sell immediately? Or is it worth buying Nvidia?

Yet, the market’s reaction was frosty. This follows a decline of roughly 16% for the stock in November, with downward pressure continuing at the start of the new week. Market observers characterize this as a classic “sell the news” event, where anticipated positive developments become a catalyst for profit-taking. A growing sentiment among some investors is that the AI investment boom may have become overheated, contributing to the cautious stance.

Internal Mobilization and Upcoming Investor Scrutiny

Alongside the Microsoft announcement, CEO Jensen Huang addressed the company’s workforce in a broad internal communication. His core message focused on the intensified internal use of Nvidia’s own AI agents, signaling management’s serious commitment to the technology and a desire to lead by example.

The next significant test for market sentiment arrives imminently. Nvidia is scheduled to present at the UBS Global Technology and AI Conference. Investors will be listening closely for clear guidance on the investment intentions of major cloud providers for 2026. The prevailing mood is unlikely to shift unless Huang can convincingly argue that the substantial capital expenditure from hyperscale cloud companies will persist. Until then, the stock remains vulnerable to further pressure, despite its premier fundamental standing.

Ad

Nvidia Stock: Buy or Sell?! New Nvidia Analysis from February 7 delivers the answer:

The latest Nvidia figures speak for themselves: Urgent action needed for Nvidia investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Nvidia: Buy or sell? Read more here...

Tags: Nvidia
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

OneSpan Stock
Cyber Security

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026
Viking Therapeutics Stock
Earnings

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

February 7, 2026
Diginex Stock
Blockchain

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026
Next Post
Meta Stock

Meta Shares Face Dual Headwinds Amid Growth Concerns

Strategy Stock

MicroStrategy's Bitcoin Exit Strategy: How Close Is the Trigger Point?

Intel Stock

A Potential Turning Point for Intel: Apple Deal Sparks Investor Optimism

Recommended

Super Micro Computer Stock

Super Micro Stock Surges Amid AI Infrastructure Boom

4 months ago
Adobe Stock

Adobe’s AI Ambitions Face Investor Skepticism

4 months ago
IBM Stock

Strong IBM Earnings Fail to Impress Market as Key Segment Shows Weakness

4 months ago
Inozyme Pharma Inc Stock

Inozyme Pharma Acquisition Finalized: Strategic Focus Shifts to Clinical Development

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

Investors Await March Report for Boston Omaha’s Strategic Direction

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

Trending

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

by Rodolfo Hanigan
February 7, 2026
0

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business...

CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio
  • A New Chapter for First Busey as CrossFirst Merger Finalizes
  • Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com